سوق علاج وتشخيص سرطان المثانة - النمو ، والاتجاهات ، وتأثير COVID-19 ، والتنبؤات (2023 - 2028)

Table of Contents

1. 1. INTRODUCTION

   1. 1.1 Study Deliverables

   2. 1.2 Study Assumptions

   3. 1.3 Scope of the Study

2. 2. RESEARCH METHODOLOGY

3. 3. EXECUTIVE SUMMARY

4. 4. MARKET DYNAMICS

   1. 4.1 Market Overview

   2. 4.2 Market Drivers

      1. 4.2.1 Increasing Awareness on Bladder Diseases and Available Therapies

      2. 4.2.2 Increasing Healthcare Expenditure

      3. 4.2.3 Increasing Burden of Bladder Cancer

   3. 4.3 Market Restraints

      1. 4.3.1 Rise in the Number of Patent Expiration and Increased Use of Generic Drugs

      2. 4.3.2 Asymptomatic Nature of the Disease

   4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

5. 5. MARKET SEGMENTATION

   1. 5.1 By Product

      1. 5.1.1 By Therapeutics

         1. 5.1.1.1 Chemotherapy

         2. 5.1.1.2 Immunotherapy

         3. 5.1.1.3 Other Therapeuticss

      2. 5.1.2 By Diagnostics

         1. 5.1.2.1 Cystoscopy

         2. 5.1.2.2 Bladder Ultrasound

         3. 5.1.2.3 Urinalysis

         4. 5.1.2.4 Other Diagnostics

   2. 5.2 By Cancer Type

      1. 5.2.1 Transitional Cell Bladder Cancer

      2. 5.2.2 Squamous Cell Bladder Cancer

      3. 5.2.3 Other Cancer Types

   3. 5.3 By Geography

      1. 5.3.1 North America

         1. 5.3.1.1 United States

         2. 5.3.1.2 Canada

         3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

         1. 5.3.2.1 Germany

         2. 5.3.2.2 United Kingdom

         3. 5.3.2.3 France

         4. 5.3.2.4 Italy

         5. 5.3.2.5 Spain

         6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

         1. 5.3.3.1 China

         2. 5.3.3.2 Japan

         3. 5.3.3.3 India

         4. 5.3.3.4 Australia

         5. 5.3.3.5 South Korea

         6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

         1. 5.3.4.1 GCC

         2. 5.3.4.2 South Africa

         3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

         1. 5.3.5.1 Brazil

         2. 5.3.5.2 Argentina

         3. 5.3.5.3 Rest of South America

6. 6. COMPETITIVE LANDSCAPE

   1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Bristol-Myers Squibb Company

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 GlaxoSmithKline PLC

      6. 6.1.6 Novartis International AG

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Sanofi SA

      9. 6.1.9 Endo Pharmaceuticals Inc.

      10. 6.1.10 Johnson & Johnson (Janssen Pharmaceutical)

   *List Not Exhaustive

7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS